Revista de la Facultad de Medicina Humana
Volume 22

Issue 2

Article 2

2021

Hematopoietic stem cell transplant in peru: experience and
challenges of the largest transplant center in Perú
Lourdes Aranda-Gomero
Rafael Pichardo-Rodriguez
Universidad Ricardo Palma, Lima-Perú, rafael_martin1352@hotmail.com

Iván Fernandez-Vertíz
Alfredo Wong-Chang

Follow this and additional works at: https://inicib.urp.edu.pe/rfmh

Recommended Citation
Aranda-Gomero, Lourdes; Pichardo-Rodriguez, Rafael; Fernandez-Vertíz, Iván; and Wong-Chang, Alfredo
(2021) "Hematopoietic stem cell transplant in peru: experience and challenges of the largest transplant
center in Perú," Revista de la Facultad de Medicina Humana: Vol. 22: Iss. 2, Article 2.
DOI: https://doi.org/10.25176/RFMH.v22i2.4786
Available at: https://inicib.urp.edu.pe/rfmh/vol22/iss2/2

This Editorial is brought to you for free and open access by INICIB-URP. It has been accepted for inclusion in
Revista de la Facultad de Medicina Humana by an authorized editor of INICIB-URP.

Aranda-Gomero et al.: Hematopoietic stem cell transplant in peru: experience and challe
Rev. Fac. Med. Hum. 2022; 22(2):226-228.

DOI:10.25176/RFMH.v22i2.4786

ISSN Versión Online: 2308-0531

Facultad de Medicina Humana URP

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PERU: EXPERIENCE AND CHALLENGES OF THE
LARGEST TRANSPLANTATION CENTER IN PERU
TRASPLANTE DE CÉLULAS MADRE HEMATOPOYÉTICAS EN EL PERÚ: EXPERIENCIA Y DESAFÍOS
DEL CENTRO DE TRASPLANTE MÁS GRANDE DEL PERÚ
Lourdes Aranda-Gomero1, Rafael Pichardo-Rodriguez 2, Ivan Fernandez-Vertíz 1, Alfredo Wong-Chang 1,2

Bone marrow transplantation, currently known as hematopoietic stem cell transplant (HSCT), involves the
infusion of stem cells healthy hematopoietic cells to patients with dysfunctional bone marrow, diminished or
compromised by hematological neoplasms (1). Since its rst exploration in humans in the 1950s based on the
results obtained in animal models, more than one million procedures have now been performed in Europe and
collaborating countries. Early detection of complications and histocompatibility typing (HLA) with which
potential donors can be better-selected thanks to an international donor registry network of bone marrow and
the advancement of technology in terms of support treatment (2-4).
HEMATOPOIETIC STEM TRANSPLANTATION IN LATIN AMERICA AND PERU
The rst transplants performed in Latin America began in the 1980s, and the number has been increasing
continuously since(5). In Peru, starting in 1994, the rst transplants began to be performed. Since that date, the
bone marrow transplant unit (UTMO) of the "Edgardo Rebagliati Martins" National Hospital (HNERM) as well as
a few other Peruvians centers, has been carrying out HPT in its diﬀerent modalities: Autologous transplants in
which the same patient is the donor of their cells, Compatible Allogeneic Transplantation in which a
consanguineous sibling donates the cells as they are 100% compatible according to their HLA and nally from
the 2015 a new unique methodology in the country that allows transplants with direct relatives of the same
family nucleus (Parents and Siblings) who only present 50% of the compatibility also known as Haploidentical
. This experience is demonstrated with more than 1500 transplants performed.

(1,6)

Currently, by the year 2022, at the national level, there were only seven health establishments accredited by the
Ministry of Health to carry out TPH7. Only 4 of these centers are authorized to perform allogeneic transplants,
which are the priority in pediatric patients with leukemia(7). The HNERM UTMO service has contributed to more
than half of all transplants performed nationwide, which by 2020 were 155 procedures.
PROFILE OF THE PATIENTS UNDERGOING HSCT
Among the characteristics of the patients undergoing HSCT in our unit, the most frequent gender in general for
all transplants was male, aged between 18 and 51 years. Table 1 summarizes the pro les of patients
undergoing HSCT at the UTMO of the HNERM.
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SURVIVAL OF TRANSPLANTED PATIENTS IN THE

PERSPECTIVES FOR THE FUTURE

UTMO

Since its creation in 1994, the UTMO of the HNERM has

It has been possible to achieve an overall survival at 60

been making continuous eﬀorts to provide a warm

months (5 years) in our patients of 75% for allogeneic

service with the highest quality standards to patients

TPH and up to 55% for haploidentical TPH. Figures 1 and

with diseases that compromise the functioning of the

2 show the survival curves estimated by Kaplan-Meier.

bone marrow, oﬀering an opportunity for treatment

On the other hand, the overall survival for patients

and in some cases, even the cure of highly aggressive

undergoing autologous HPCT at 5 years is only 50%.

pathologies (1).

IMPACT OF THE COVID-19 PANDEMIC ON THE TPH

Despite the progressive increase in procedures
performed at the national level, access to bone marrow

PROGRAM
The pandemic caused by coronavirus disease 2019,
better known as COVID-19, which was declared in
March 2020, has generated a global health crisis, with a
signi cant impact on bone marrow transplant units
around the world (8).

transplantation is still insuﬃcient, so greater eﬀorts are
required to close this infrastructure gap.

In this year, after the ravages caused by the pandemic,
we want to be able to continue growing as a unit and
implementing new technologies and transplant
platforms such as the unrelated, the promotion and

The UTMO of the HNERM had a negative impact,
reducing by 40% the number of transplants performed
during the year 2020 compared to the previous year. It

implementation of a scienti c research unit that allows
speci c analyzes of our population, such as the
evaluation of the quality of life after transplantation, as

found an incidence of 13.5%, with mild cases being the

well as the development of cell therapy that allows us to

most frequent group (83%) followed by severe cases

improve our transplant processes and obtain the best

(17%) and lethality of 8%, three times above the average

possible results for the sake of patient health. For this

Peruvian population. It was also found that only 25%

reason, we thank all our patients for the trust placed in

required speci c treatment for symptoms.

the HNERM UTMO to treat their diseases.

Table 1.

Pro le of patients undergoing HSCT in the UTMO of the HNERM

Age
gender
Diagnosis
Donor
Blood group

Allogeneic

Haploidentical

Autologous

30 years

18,5 years

51 years

Man

Man

Man

B-ALL

B-ALL

Multiple myeloma

Brother

Father

Doesn’t apply / Does not apply

O+

O+

O+

*Leucemia linfoblástica aguda B
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Figure 1. Survival in patients undergoing transplantation at the UTMO of the HNERM
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Figure 2. Survival in patients undergoing haploidentical transplantation at the UTMO of the HNERM
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